Avalon GloboCare Partners with SpecialtyHealth, Inc. to Power Police Chiefs’ Fitness Challenge with KetoAir
Avalon GloboCare (NASDAQ: ALBT) has partnered with SpecialtyHealth to enhance the BrAce 4 Impact Challenge (B4IC) using their KetoAir™ breathalyzer. The collaboration, launched on April 1, 2024, integrates SpecialtyHealth into Avalon's Zero to Keto Affiliate Marketing Program and B4IC Series.
The program combines Pounds Transformation's 4-week diet program with SpecialtyHealth's 'Famous Police Panel' wellness initiatives, targeting police chiefs across multiple states. The KetoAir™ device, FDA-registered (number: 3026284320), measures breath acetone concentration to track ketosis levels through nano-sensor technology.
This partnership focuses on supporting law enforcement officers in maintaining their health goals through real-time ketone monitoring. The device's pocket-sized design allows officers to check their ketone levels between shifts, providing immediate feedback and accountability in their wellness journey.
Avalon GloboCare (NASDAQ: ALBT) ha collaborato con SpecialtyHealth per migliorare la BrAce 4 Impact Challenge (B4IC) utilizzando il loro alcolimetro KetoAir™. La collaborazione, avviata il 1° aprile 2024, integra SpecialtyHealth nel programma di marketing affiliato Zero to Keto di Avalon e nella serie B4IC.
Il programma unisce il programma dietetico di 4 settimane di Pounds Transformation con le iniziative benessere 'Famous Police Panel' di SpecialtyHealth, rivolte ai capi della polizia in diversi stati. Il dispositivo KetoAir™, registrato dalla FDA (numero: 3026284320), misura la concentrazione di acetone nel respiro per monitorare i livelli di chetosi grazie alla tecnologia nano-sensore.
Questa partnership si concentra sul supporto agli agenti delle forze dell'ordine nel mantenere i propri obiettivi di salute tramite il monitoraggio in tempo reale dei chetoni. Il design tascabile del dispositivo consente agli agenti di controllare i livelli di chetoni tra un turno e l'altro, offrendo un feedback immediato e responsabilità nel loro percorso di benessere.
Avalon GloboCare (NASDAQ: ALBT) se ha asociado con SpecialtyHealth para mejorar el BrAce 4 Impact Challenge (B4IC) utilizando su alcoholímetro KetoAir™. La colaboración, lanzada el 1 de abril de 2024, integra a SpecialtyHealth en el Programa de Marketing de Afiliados Zero to Keto de Avalon y en la serie B4IC.
El programa combina el plan de dieta de 4 semanas de Pounds Transformation con las iniciativas de bienestar 'Famous Police Panel' de SpecialtyHealth, dirigidas a jefes de policía en varios estados. El dispositivo KetoAir™, registrado por la FDA (número: 3026284320), mide la concentración de acetona en el aliento para rastrear los niveles de cetosis mediante tecnología de nano-sensores.
Esta alianza se enfoca en apoyar a los agentes de la ley para mantener sus objetivos de salud a través del monitoreo en tiempo real de cetonas. El diseño compacto del dispositivo permite a los oficiales verificar sus niveles de cetonas entre turnos, proporcionando retroalimentación inmediata y responsabilidad en su camino hacia el bienestar.
Avalon GloboCare (NASDAQ: ALBT)는 SpecialtyHealth와 협력하여 KetoAir™ 호흡 측정기를 활용한 BrAce 4 Impact Challenge (B4IC)를 강화했습니다. 2024년 4월 1일 시작된 이번 협업은 SpecialtyHealth를 Avalon의 Zero to Keto 제휴 마케팅 프로그램과 B4IC 시리즈에 통합합니다.
이 프로그램은 Pounds Transformation의 4주 다이어트 프로그램과 SpecialtyHealth의 'Famous Police Panel' 웰니스 이니셔티브를 결합하여 여러 주의 경찰서장들을 대상으로 합니다. FDA 등록 번호 3026284320인 KetoAir™ 장치는 나노 센서 기술을 통해 호흡 중 아세톤 농도를 측정하여 케토시스 수준을 추적합니다.
이번 파트너십은 법 집행관들이 실시간 케톤 모니터링을 통해 건강 목표를 유지할 수 있도록 지원하는 데 중점을 둡니다. 휴대가 간편한 이 장치는 경찰관들이 교대 근무 사이에 케톤 수치를 확인할 수 있게 하여 즉각적인 피드백과 책임감을 제공합니다.
Avalon GloboCare (NASDAQ : ALBT) s'est associé à SpecialtyHealth pour renforcer le BrAce 4 Impact Challenge (B4IC) grâce à leur éthylotest KetoAir™. Cette collaboration, lancée le 1er avril 2024, intègre SpecialtyHealth au programme de marketing d'affiliation Zero to Keto d'Avalon ainsi qu'à la série B4IC.
Le programme combine le programme alimentaire de 4 semaines de Pounds Transformation avec les initiatives bien-être 'Famous Police Panel' de SpecialtyHealth, ciblant les chefs de police de plusieurs États. Le dispositif KetoAir™, enregistré auprès de la FDA (numéro : 3026284320), mesure la concentration d'acétone dans l'haleine pour suivre les niveaux de cétose grâce à une technologie de nano-capteurs.
Ce partenariat vise à soutenir les agents des forces de l'ordre dans le maintien de leurs objectifs de santé grâce à une surveillance en temps réel des cétones. Le format compact de l'appareil permet aux agents de vérifier leur taux de cétones entre les services, offrant un retour immédiat et une responsabilisation dans leur parcours de bien-être.
Avalon GloboCare (NASDAQ: ALBT) hat sich mit SpecialtyHealth zusammengeschlossen, um die BrAce 4 Impact Challenge (B4IC) mit ihrem KetoAir™ Atemalkoholmessgerät zu verbessern. Die Zusammenarbeit, die am 1. April 2024 gestartet wurde, integriert SpecialtyHealth in Avalons Zero to Keto Affiliate Marketing Programm und die B4IC-Serie.
Das Programm kombiniert Pounds Transformations 4-Wochen-Diätprogramm mit den Wellness-Initiativen des 'Famous Police Panel' von SpecialtyHealth, die sich an Polizeichefs in mehreren Bundesstaaten richten. Das KetoAir™ Gerät, FDA-registriert (Nummer: 3026284320), misst die Acetonkonzentration im Atem, um Ketosewerte mittels Nanotechnologie zu verfolgen.
Diese Partnerschaft konzentriert sich darauf, Strafverfolgungsbeamte bei der Erreichung ihrer Gesundheitsziele durch Echtzeit-Ketonüberwachung zu unterstützen. Das taschengroße Design des Geräts ermöglicht es den Beamten, ihre Ketonwerte zwischen den Schichten zu überprüfen und so sofortiges Feedback und Verantwortung auf ihrem Wellness-Weg zu erhalten.
- Strategic partnership expansion with SpecialtyHealth enhances market reach in law enforcement sector
- FDA-registered KetoAir device demonstrates regulatory compliance
- Multi-platform availability (Apple App Store and Google Play Store) increases accessibility
- None.
Avalon’s KetoAir™ breathalyzer used to maintain progress for law enforcement to establish and meet their BrAce goals during the ongoing BrAce 4 Impact Challenge
FREEHOLD, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, today announced the addition of SpecialtyHealth, Inc. (“SpecialtyHealth”) — co-founded by Dr. EJ Greenwald, the pioneer of the “Famous Police Panel” — as a strategic partner. SpecialtyHealth will be integrated into Avalon’s Zero to Keto Affiliate Marketing Program and the BrAce 4 Impact Challenge (“B4IC”) Series, where it will serve as a co-administrator for the ongoing B4IC, launched on April 1, 2024.
In collaboration with Pounds Transformation (“PT”), this challenge merges PT’s 4-week diet program with SpecialtyHealth’s “Famous Police Panel” and wellness initiatives. Police chiefs across multiple states are participating in the B4IC, integrating the KetoAir™ breathalyzer as a motivational tool to support their progress throughout the program.
“The KetoAir™ breathalyzer fits perfectly in a uniform pocket, making it easy for officers to check their ketone levels throughout the day and between shifts,” said Dr. Greenwald. “It’s an excellent tool to help them monitor their body’s daily use of ketones and stay on track with our weight management program for better health.”
“Integrating the KetoAir™ breathalyzer into our programs helps patients track their ketone levels in real time, keeping them motivated and engaged,” said Dr. Charles Cavo, Co-founder of PT. “For many who’ve struggled with weight loss, KetoAir™ provides immediate feedback that reinforces progress and accountability. We’re proud to partner with SpecialtyHealth and support our first responder community as they navigate high-stress environments and make healthier choices.”
The inaugural KetoAirTM B4IC brings together a select group of police chiefs and law enforcement leaders. Each participant has completed the “Famous Police Panel” and is now focused on building healthier habits by managing ketone levels as part of their wellness journey.
This first group will set the standard for future first responder programs, helping integrate a ketogenic approach into their demanding daily routines. With guidance from dedicated coaches like Chief Flannelly, and the combined expertise of PT and SpecialtyHealth, participants are learning how to naturally boost ketone production for better everyday health.
“With 20 years of experience in wellness and prevention, SpecialtyHealth is excited to introduce KetoAir to our programs — it’s a game changer,” said Dr. Greenwald.
David Jin, M.D., Ph.D., Avalon’s CEO, commented, “We’re pleased to expand our partnership with PT to include SpecialtyHealth and their first responder network. It’s rewarding to see the KetoAir™ device driving real-time, personalized insights that support this vital workforce. This collaboration reflects our shared commitment to innovative, accessible tools that improve health and promote lasting lifestyle changes.”
KetoAir™ is a handheld breathalyzer, specifically engineered for ketogenic health management (U.S. Food and Drug Administration registration number: 3026284320). KetoAir™ measures an individual's breath acetone concentration (BrAce), a ketone body that rises as fat oxidation increases. By leveraging the nano-sensor-based technology, the KetoAir™ breathalyzer is designed to assess the ketosis status of its individual user and is accessible on both the Apple App Store and Google Play Store.
To learn more or purchase your own KetoAir™ device, visit www.ketoair.us.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products and the advancement of intellectual property in cellular therapy. Avalon is currently marketing the KetoAir™ breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAirTM is registered with the U.S. Food and Drug Administration as a Class I medical device. In addition, Avalon owns and operates commercial real estate. For more information about Avalon, please visit www.avalon-globocare.com.
Forward-Looking Statements
Certain statements contained in this press release are “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “should”, “may”, and other words and terms of similar meaning or use of future dates; however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the ability to enter into a definitive agreement, as well as the Company’s commercialization, distribution and sales of KetoAirTM and the product’s ability to compete with other testing methods for determining ketosis. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission (the “SEC”), accessible through the SEC’s website (http://www.sec.gov), including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed or furnished with the SEC. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors, including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. The Company disclaims any obligation to update forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release. The contents of any website referenced in this press release are not incorporated by reference herein.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9 South, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com
FAQ
What is the BrAce 4 Impact Challenge launched by Avalon GloboCare (ALBT) in April 2024?
How does the KetoAir breathalyzer technology by ALBT work for ketosis tracking?
What is the FDA registration status of ALBT's KetoAir device?
Where can users access the ALBT KetoAir device's companion app?
